Latest News and Press Releases

HUDDINGE, Sweden, Dec. 1, 2003 (PRIMEZONE) -- Peptimmune, Inc. and Medivir today announced the issuance of a European patent claiming uses of Cathepsin S inhibitors in therapeutic formulations for...

HUDDINGE, Sweden, Nov. 19, 2003 (PRIMEZONE) -- Medivir (Huddinge, Sweden) and Jiangsu Hengrui Medicine Company (Shanghai, Peoples Republic of China) have entered a discovery collaboration to jointly...

HUDDINGE, Sweden, Nov. 19, 2003 (PRIMEZONE) -- Roche and Medivir announced today a new research agreement in the area of hepatitis C (HCV) and the restructuring of their current alliance in the area...

HUDDINGE, Sweden, Oct. 23, 2003 (PRIMEZONE) -- In July, Medivir entered a licensing agreement with Boehringer Ingelheim (BI) on MIV-310. - CCS group divested to the Segulah II L.P. investment fund...

HUDDINGE, Sweden, July 30, 2003 (PRIMEZONE) -- MIV-150 has been outlicensed to Population Council in New York for usein a microbicide intended to prevent HIV transmission. The PopulationCouncil has...

HUDDINGE, Sweden, July 15, 2003 (PRIMEZONE) -- Medivir will host a teleconference on 15 July at 13.00 SE time. Lars Adlersson CEO, Johan Harmenberg VP Pharmaceutical Development and Rein Piir CFO/IR,...

HUDDINGE, Sweden, July 15, 2003 (PRIMEZONE) -- Boehringer Ingelheim and Medivir sign agreement for novel HIV/AIDS antiviral - MIV-310, as a possible treatment for multi-drug resistant patients...

HUDDINGE, Sweden, July 9, 2003 (PRIMEZONE) -- Medivir: Interim Report, 1 January - 30 June 2003 - In May, Medivir reached a licensing agreement on MIV-210 with GlaxoSmithKline; EUR 6 m was received...

HUDDINGE, Sweden, June 18, 2003 (PRIMEZONE) -- Medivir and Segulah II L.P. announce the signing of a transfer agreement implying Segulah II L.P. acquiring Medivir subsidiary CCS, Clean Chemical...

HUDDINGE, Sweden, May 21, 2003 (PRIMEZONE) -- Medivir will host a teleconference on 21 May at 11:00 SE time. Lars Adlersson CEO, Johan Harmenberg VP Pharmaceutical Development and Rein Piir CFO/IR,...